@article{TRO4167,
author = {Sheng-Hung Wang and Chu-Ping Pi and Tung-Hao Chang and Mu-Tai Liu and Chia-Chun Huang and Li-Chung Hung and Tsai-Wei Chou and Yu-Jun Chang},
title = {The impacts of chemotherapeutic response for clinical stage II and III breast cancer patients after neoadjuvant chemotherapy},
journal = {Therapeutic Radiology and Oncology},
volume = {2},
number = {3},
year = {2018},
keywords = {},
abstract = {Background: Neoadjuvant chemotherapy (NAC) has been an increase in the utilization of neoadjuvant treatment for invasive breast cancer over the last decade. In this study, we assess outcomes between responders and non-responders after NAC in patients with clinical stage II and III breast cancer.
Methods: In total, 133 patients with clinical stage II and III invasive breast ductal carcinoma (IDC) treated with anthracycline- or taxane-based NAC, followed by surgery and adjuvant radiotherapy between April 2007 and December 2012, were retrospectively reviewed and assigned as responders [complete or partial response (PR)] or non-responders (stable or progressive disease), based on clinical and pathological assessments.
Results: The median follow up time was 59.2 months (range, 12.3–110 months). After NAC, 89 patients were responders, whereas 44 patients were non-responders. For the responders and non-responders, overall survival (OS) was 94.5 and 78.2 months (95% CI, 89.2–99.8 and 67.0–89.4, P=0.007), and relapse-free survival (RFS) was 85.5 and 59.9 months (95% CI, 78.3–92.6 and 47.3–72.4, P},
issn = {2616-2768}, url = {https://tro.amegroups.org/article/view/4167}
}